Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults
<strong>Background</strong> T-cell responses against highly conserved influenza antigens have been previously associated with protection. However, these immune responses are poorly maintained following recovery from influenza infection and are not boosted by inactivated influenza vaccine...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2018
|
| _version_ | 1797068849467621376 |
|---|---|
| author | Coughlan, L Sridhar, S Payne, R Edmans, E Milicic, A Venkatraman, N Lugonja, B Clifton, L Qi, C McMichael, A Folegatti, PM Lawrie, AM Roberts, R de Graaf, H Sukhtankar, P Faust, SN Lewis, DJM Lambe, T Hill, AVS Gilbert, SC |
| author_facet | Coughlan, L Sridhar, S Payne, R Edmans, E Milicic, A Venkatraman, N Lugonja, B Clifton, L Qi, C McMichael, A Folegatti, PM Lawrie, AM Roberts, R de Graaf, H Sukhtankar, P Faust, SN Lewis, DJM Lambe, T Hill, AVS Gilbert, SC |
| author_sort | Coughlan, L |
| collection | OXFORD |
| description | <strong>Background</strong> T-cell responses against highly conserved influenza antigens have been previously associated with protection. However, these immune responses are poorly maintained following recovery from influenza infection and are not boosted by inactivated influenza vaccines. We have previously demonstrated the safety and immunogenicity of two viral vectored vaccines, modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAdOx1 expressing conserved influenza virus antigens, nucleoprotein (NP) and matrix protein-1 (M1). We now report on the safety and long-term immunogenicity of multiple combination regimes of these vaccines in young and older adults. <strong>Methods</strong> We conducted a Phase I open-label, randomized, multi-center study in 49 subjects aged 18–46 years and 24 subjects aged 50 years or over. Following vaccination, adverse events were recorded and the kinetics of the T cell response determined at multiple time points for up to 18 months. <strong>Findings</strong> Both vaccines were well tolerated. A two dose heterologous vaccination regimen significantly increased the magnitude of pre-existing T-cell responses to NP and M1 after both doses in young and older adults. The fold-increase and peak immune responses after a single MVA-NP + M1 vaccination was significantly higher compared to ChAdOx1 NP + M1. In a mixed regression model, T-cell responses over 18 months were significantly higher following the two dose vaccination regimen of MVA/ChAdOx1 NP + M1. <strong>Interpretation</strong> A two dose heterologous vaccination regimen of MVA/ChAdOx1 NP + M1 was safe and immunogenic in young and older adults, offering a promising vaccination strategy for inducing long-term broadly cross-reactive protection against influenza A. |
| first_indexed | 2024-03-06T22:15:54Z |
| format | Journal article |
| id | oxford-uuid:5360e7ba-ace2-4886-b57b-f8e8acb45025 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T22:15:54Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:5360e7ba-ace2-4886-b57b-f8e8acb450252022-03-26T16:31:18ZHeterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adultsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5360e7ba-ace2-4886-b57b-f8e8acb45025Symplectic Elements at OxfordElsevier2018Coughlan, LSridhar, SPayne, REdmans, EMilicic, AVenkatraman, NLugonja, BClifton, LQi, CMcMichael, AFolegatti, PMLawrie, AMRoberts, Rde Graaf, HSukhtankar, PFaust, SNLewis, DJMLambe, THill, AVSGilbert, SC<strong>Background</strong> T-cell responses against highly conserved influenza antigens have been previously associated with protection. However, these immune responses are poorly maintained following recovery from influenza infection and are not boosted by inactivated influenza vaccines. We have previously demonstrated the safety and immunogenicity of two viral vectored vaccines, modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAdOx1 expressing conserved influenza virus antigens, nucleoprotein (NP) and matrix protein-1 (M1). We now report on the safety and long-term immunogenicity of multiple combination regimes of these vaccines in young and older adults. <strong>Methods</strong> We conducted a Phase I open-label, randomized, multi-center study in 49 subjects aged 18–46 years and 24 subjects aged 50 years or over. Following vaccination, adverse events were recorded and the kinetics of the T cell response determined at multiple time points for up to 18 months. <strong>Findings</strong> Both vaccines were well tolerated. A two dose heterologous vaccination regimen significantly increased the magnitude of pre-existing T-cell responses to NP and M1 after both doses in young and older adults. The fold-increase and peak immune responses after a single MVA-NP + M1 vaccination was significantly higher compared to ChAdOx1 NP + M1. In a mixed regression model, T-cell responses over 18 months were significantly higher following the two dose vaccination regimen of MVA/ChAdOx1 NP + M1. <strong>Interpretation</strong> A two dose heterologous vaccination regimen of MVA/ChAdOx1 NP + M1 was safe and immunogenic in young and older adults, offering a promising vaccination strategy for inducing long-term broadly cross-reactive protection against influenza A. |
| spellingShingle | Coughlan, L Sridhar, S Payne, R Edmans, E Milicic, A Venkatraman, N Lugonja, B Clifton, L Qi, C McMichael, A Folegatti, PM Lawrie, AM Roberts, R de Graaf, H Sukhtankar, P Faust, SN Lewis, DJM Lambe, T Hill, AVS Gilbert, SC Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults |
| title | Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults |
| title_full | Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults |
| title_fullStr | Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults |
| title_full_unstemmed | Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults |
| title_short | Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults |
| title_sort | heterologous two dose vaccination with simian adenovirus and poxvirus vectors elicits long lasting cellular immunity to influenza virus a in healthy adults |
| work_keys_str_mv | AT coughlanl heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT sridhars heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT payner heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT edmanse heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT milicica heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT venkatramann heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT lugonjab heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT cliftonl heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT qic heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT mcmichaela heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT folegattipm heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT lawrieam heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT robertsr heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT degraafh heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT sukhtankarp heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT faustsn heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT lewisdjm heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT lambet heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT hillavs heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults AT gilbertsc heterologoustwodosevaccinationwithsimianadenovirusandpoxvirusvectorselicitslonglastingcellularimmunitytoinfluenzavirusainhealthyadults |